Activin type II receptor ligands (ActRII ligands)

Activin and Growth Differentiation Factor (GDF) ligands are members of the Transforming Growth Factor-beta (TGF-beta) superfamily that regulate diverse physiological processes, including erythropoiesis, vascular homeostasis, and muscle growth (UniProt, 2024). These ligands, specifically Activin A, Activin B, GDF8 (Myostatin), and GDF11, signal by binding to Activin Type II receptors (ActRIIA or ActRIIB), which then recruit Type I receptors to activate the Smad2/3 signaling pathway (PubMed: 37018456). In diseases such as pulmonary arterial hypertension (PAH), an overabundance of these ligands leads to an imbalance between pro-proliferative Smad2/3 and anti-proliferative Smad1/5/8 signaling, resulting in pathological vascular remodeling (NEJM, 2023). Therapeutic strategies utilize soluble receptor ectodomains, such as Sotatercept (ActRIIA-Fc) and Luspatercept (modified ActRIIB-Fc), which act as "ligand traps" to sequester circulating ligands and restore signaling balance (Nature Reviews Drug Discovery, 2020). This approach has demonstrated clinical efficacy in improving exercise capacity in PAH patients and reducing transfusion burden in patients with anemia related to beta-thalassemia or myelodysplastic syndromes (FDA, 2024; NEJM, 2020). Common safety considerations for drugs targeting these ligands include monitoring for hypertension and erythrocytosis due to their potent effects on vascular tone and red blood cell maturation.

Other names

Activin AActivin BGrowth differentiation factor 8MyostatinGrowth differentiation factor 11GDF8GDF11TGF-beta superfamily ligandsInhibin beta AInhibin beta B

Ligand sequestration (ligand trap) using soluble receptor ectodomains fused to an Fc fragment to prevent ligand binding to endogenous cell-surface receptors and inhibit downstream Smad2/3 signaling.